Skip to main content
. 2007 Mar;9(3):200–206. doi: 10.1593/neo.07103

Figure 4.

Figure 4

The androgen stimulation of the VCaP and NCI-H660 prostate cancer cell lines carrying TMPRSS2-ERG fusion. PSA (red bars), ERG (exons 5 and 6; dark blue bars), and TMPRSS-ERG (TMPRSS2 exon 1 to ERG exon 4; light blue bars) expression relative to HMBS in androgen-sensitive VCaP cells (A) and androgen-insensitive NCI-H660 cells (B) was assessed by qPCR. Cell lines were incubated with vehicle or 10 µM of the AR antagonist flutamide for 2 hours before treatment for 24 hours with 0.5 or 5 nM of the synthetic androgen R1881 or vehicle, as indicated. Relative amounts of PSA, ERG, or TMPRSS2-ERG per HMBS were compared for VCaP and NCI-H660.